• ABOUT US
    ▼
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    ▼
    • Our Approach
    • Publications
    • Conferences
  • PROGRAMS
    ▼
    • Pipeline
    • VIS171
    • VIS513
  • FOR PATIENTS
    ▼
    • Clinical Trials
  • CAREERS
    ▼
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

Visterra

We Bring Better Biologics to Life

  • ABOUT US
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    • Our Approach
    • Publications
    • Conferences
  • PROGRAMS
    • Pipeline
    • VIS171
    • VIS513
  • FOR PATIENTS
    • Clinical Trials
  • CAREERS
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

VIS954 is a Potent Anti-C5aR1 Antibody for the Treatment of ANCA-Associated Vasculitis

May 26, 2023 | 15th International Conference on Complement Therapeutics
Lauren Olinski, et al.

VIS954 is a Potent Anti-C5aR1 Antibody for the Treatment of ANCA-Associated Vasculitis

Lauren Olinski, Danielle Wisheart, Daisuke Oka, Lisa Perreault, Boopathy Ramakrishnan, A. Richard Kitching, Gregory Babcock, Zachary Shriver, Karthik Viswanathan

© 2025 Visterra, Inc. Terms of usePrivacy PolicySite Design: Fassino/Design

We use cookies on our website to see how you interact with it. By accepting, you agree to our use of such cookies. Privacy PolicyOk